Moderna’s COVID-19 vaccine is 96% effective in teens, trial shows. The pharmaceutical company announced that its vaccine is effective and safe for kids aged 12 to 17 years old. 

3,235 volunteers and 12 recorded virus cases have participated in the trial. Moderna’s vaccine, a two-dose shot, has been approved for emergency use in adults aged 18 and older. 

Moderna’s trial results come as Pfizer’s coronavirus vaccine is in line to receive authorization for emergency use for teens aged 12 to 15 years old. Pfizer’s vaccine for 16 and 17 years old has already been approved. 

Moderna says that the vaccine was “generally well tolerated with no serious safety concerns identified to date.” 

The company also announced that results from a trial testing booster shots against virus variants show that a single “booster dose” increases neutralizing antibodies against two variants in previously vaccinated trial volunteers.

Moderna added that it is testing its vaccine in adults with kidney or liver transplants. 

The pharmaceutical company also announced its vaccine projection for the year, which will be between 800 million to 1 billion doses. Aside from that, the company is also making other investments to increase its global vaccine supply up to 3 billion doses by 2022.